A Retrospective Analysis of Pegylated Liposomal Doxorubicin in Ovarian Cancer: Do We Still Need It?

Journal of Ovarian Research - United Kingdom
doi 10.1186/1757-2215-6-10
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Emerging Pharmacotherapies in Ovarian Cancer: Focus on Pegylated Liposomal Doxorubicin

Clinical Medicine Reviews in Women's Health
2010English

A Systematic Review and Economic Evaluation of Pegylated Liposomal Doxorubicin Hydrochloride for Ovarian Cancer

Health Technology Assessment
MedicineHealth Policy
2002English

Non‑pegylated Liposomal Doxorubicin for Patients With Recurrent Ovarian Cancer: A Multicentric Phase II Trial

Oncology Letters
Cancer ResearchOncology
2016English

Efficacy and Safety of Non-Pegylated Liposomal Doxorubicin in Metastatic Breast Cancer Therapy

OnCOReview
Oncology
2017English

Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer

PLoS ONE
Multidisciplinary
2013English

Golden Rice: No Progress to Be Seen. Do We Still Need It?

Environment and Development Economics
DevelopmentEconomicsEconometricsEnvironmental Science
2016English

Do We Still Need Bicarb? 329

Pediatric Research
Child HealthPediatricsPerinatology
1998English

Involuntary Sterilisation: We Still Need to Guard Against It

BMJ Sexual and Reproductive Health
GynecologyReproductive MedicineObstetrics
2018English

Squamous Cell Carcinoma of the Oral Cavity in a Woman With a 9-Year History of Ovarian Cancer: Is Exposure to Pegylated Liposomal Doxorubicin a Factor?

Oncologist
Cancer ResearchMedicineOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy